Use of pembrolizumab in MSI-high uterine leiomyosarcoma; a case report and review of the literature

• Overall prognosis of uterine leiomyosarcoma (ULMS) is poor with a low 5-year survival rate. • Microsatellite instability (MSI)-high ULMS is not well documented in current literature. • Immune checkpoint inhibitors such as pembrolizumab have been shown to have good efficacy in treating MSI-high sol...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gynecol Oncol Rep
Main Authors: Wang, Yannan J., Williams, Heather R., Brzezinska, Bogna N., Gaidis, Anna, Patel, Bhavi, Munroe, Janet, White, Joseph, Rungruang, Bunja
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2021
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7843391/
https://ncbi.nlm.nih.gov/pubmed/33537390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.gore.2021.100701
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados